1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fovista (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Fovista (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Summary

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Fovista is a first-in-class anti-platelet-derived growth factor (anti-PDGF) agent being developed by Ophthotech for the treatment of wAMD as a combination therapy with an anti-VEGF drug, such as Lucentis, Avastin, or Eylea. The company is currently conducting a Phase III clinical program consisting of three large trials that are investigating the efficacy of Fovista combination therapy with anti-VEGF agents in comparison with anti-VEGF monotherapy, which is the current standard of care across the 7MM.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fovista including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fovista for the top country from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Fovista performance.
- Obtain sales forecast for Fovista from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).

Table Of Contents

Fovista (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 11
2.1 Related Reports 12
3 Disease Overview 14
3.1 Macular Degeneration Overview 14
3.1.1 Etiology and Pathophysiology 16
3.1.2 Classification 20
3.1.3 Symptoms and Diagnosis 22
3.2 Macular Edema Overview 25
3.2.1 Etiology and Pathophysiology 26
3.2.2 Classification 29
3.2.3 Symptoms and Diagnosis 30
4 Disease Management 33
4.1 Diagnosis and Treatment Overview 33
4.1.1 Macular Edema Diagnosis 33
4.1.2 Macular Degeneration Diagnosis 33
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 34
4.1.4 Clinical Practice 36
5 Competitive Assessment 50
5.1 Overview 50
6 Unmet Need and Opportunity 52
6.1 Overview 52
6.2 Treatment for Dry AMD 53
6.2.1 Unmet Need 53
6.2.2 Gap Analysis 55
6.2.3 Opportunity 57
6.3 Longer-Acting Anti-VEGF Drug Therapy 59
6.3.1 Unmet Need 59
6.3.2 Gap Analysis 61
6.3.3 Opportunity 61
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 62
6.4.1 Unmet Need 62
6.4.2 Gap Analysis 63
6.4.3 Opportunity 64
6.5 Less Invasive Drug Formulations 64
6.5.1 Unmet Need 64
6.5.2 Gap Analysis 65
6.5.3 Opportunity 66
6.6 Awareness and Earlier Patient Diagnosis 67
6.6.1 Unmet Need 67
6.6.2 Gap Analysis 68
6.6.3 Opportunity 68
6.7 Home Monitoring of AMD Progression 69
6.7.1 Unmet Need 69
6.7.2 Gap Analysis 70
6.7.3 Opportunity 71
7 Pipeline Assessment 73
7.1 Overview 73
7.2 Promising Drugs in Clinical Development 74
8 Fovista 77
8.1 Overview 77
8.2 Efficacy 82
8.3 Safety 83
8.4 Dosing and Formulation 83
8.5 Potential Clinical and Commercial Positioning 83
8.6 SWOT Analysis 84
8.7 Forecast 84
9 Appendix 86
9.1 Bibliography 86
9.2 Abbreviations 100
9.3 Methodology 104
9.4 Forecasting Methodology 104
9.4.1 Diagnosed ME and AMD Patients 104
9.4.2 Percentage of Drug-Treated Patients 105
9.4.3 General Pricing Assumptions 105
9.4.4 Pricing of Pipeline Agents 106
9.5 Primary Research - KOLs Interviewed for this Report 107
9.6 Primary Research - High-Prescribers Survey 108
9.7 About the Authors 109
9.7.1 Analyst 109
9.7.2 Therapy Area Director 109
9.7.3 Global Head of Healthcare 110
9.8 About GlobalData 111
9.9 Disclaimer 111

1.1 List of Tables

Table 1: ARM System Classification of AMD 21
Table 2: Symptoms of AMD 22
Table 3: National and International Treatment Guidelines for ME and AMD 35
Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 36
Table 5: Leading Treatments for ME and AMD, 2014 51
Table 6: Unmet Needs and Opportunities in ME and AMD 53
Table 7: Promising Drugs in Clinical Development for ME and AMD 74
Table 8: Comparison of Drugs in Development for ME and AMD, 2014 75
Table 9: Product Profile - Fovista 81
Table 10: SWOT Analysis - Fovista, 2014 84
Table 11: Global Sales Forecast ($m) for Fovista, 2013-2023 85
Table 12: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 108

1.2 List of Figures

Figure 1: Anatomy of the Eye and Macula 14
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD 23
Figure 3: Color Fundus Photographs of Dry and Wet AMD 23
Figure 4: FAF Imaging of GA 24
Figure 5: Imaging of wAMD 25
Figure 6: CMT in DME 31
Figure 7: RVOs (BRVO and CRVO) on an FA 31
Figure 8: Increased CRT in ME-RVO 32
Figure 9: ME Clinical Treatment Flowchart 42
Figure 10: AMD Clinical Treatment Flowchart 49
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023 76
Figure 12: Fovista's Clinical Development in wAMD 82
Figure 13: Clinical and Commercial Positioning of Fovista 83

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Opioid Market in Iran

  • December 2016
    8 pages
  • Opioid  

  • Iran  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Related Market Segments :

Therapy
Eye Disease
Ophthalmology

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.